Genitourinary Drugs Market to grow 3.40% CAGR during the Forecast Period 2022 to 2030

Pune, India, March, 2022/MRFR Press Release/- Market Research Future has published a half-cooked research report on the global genitourinary drugs market.

Market Highlights

Genitourinary drugs are used for the treatment of medical complications related to the kidney, bladder, ureter and urethra. Genitourinary disorders are caused by damage to the urinary tract or genital organs. The increasing cases of genitourinary disorders, surge in number of people suffering from cancer, increasing prevalence of sexually transmitted diseases, and rise in number of drugs in pipeline are the major factors driving the growth of the global genitourinary drugs market. According to the Centers for Disease Control and Prevention (CDC), more than 2.3 million Americans were diagnosed  with sexually transmitted diseases in year 2017, Most common sexually transmitted diseases in American region are chlamydia, gonorrhea, and syphilis. Moreover, increase in  strategic collaborations and aggressive strategy adopted by major players in the market is also responsible for the growth of the market.

Global Genitourinary Drugs Market is projected to USD 68.04 billion by 2030 at 3.40% CAGR during forecast 2022-2030.

The increasing appearance of drug counterfeiting in pharmaceutical industry, intense competition from generic manufacturers and drug patent expirations are likely to hinder market growth during the forecast period.

Regional Analysis

The market in the Americas is expected to dominate the global genitourinary drugs market during the forecast period owing to the rising prevalence of genitourinary disorders, increasing cancer patients in the region, rise in healthcare expenditure, and the presence of a well-established healthcare system. The European market is expected to be the second-largest due to the government initiatives for the development of healthcare sector, increasing research and development activities in the region and rise in number of chronic disorders. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the increasing geriatric population, rising investments in healthcare sector and favorable government policies. The market in the Middle East & Africa is likely to account for the smallest share of the global genitourinary drugs market. The market growth in this region can be attributed to increasing healthcare expenditure and growing medical tourism.

Explore In-depth Details: Genitourinary Drugs Market Research Report

Segmentation

The global genitourinary drugs market has been segmented on the basis of disease, product, and end-user.

The market, by disease, has been classified as urinary tract infections, erectile dysfunction, urinary incontinence & overactive bladder, kidney/renal cancer, genitourinary cancer, bladder cancer, bladder cancer, cervical cancer, sexually transmitted diseases, interstitial cystitis, hematuria, ovarian cancer, and prostate cancer.

On the basis of product, the market has been segregated into urologicals, hormonal therapy, gynecologicals, and anti-infectives.

The end-user segment has been divided into, hospitals, clinics, super specialty centers, and others.

Key Players

Some of the key players in the global genitourinary drugsmarket are Bayer AG,AstraZeneca ,Abbott,Astellas Pharma Inc.,Pfizer Inc.,Eli Lilly and Company,Genentech, Inc.,Immunex Corp. GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc.,Merck & Co.,Bristol-Myers Squibb Company,Antares Pharma,and  Novartis AG